Faced with an increasingly complex system of committees, which threatens to undermine the coherence of pharmaceutical regulation in Europe, the European Medicines Agency (EMA) has come up with the perfect bureaucratic response: establish another committee.
Shares in Actelion Ltd. rose 13 percent Monday on news that macitentan, its dual endothelin receptor antagonist (ERA), hit the primary endpoint in a pivotal Phase III trial in pulmonary arterial hypertension (PAH), raising the prospect that the company will be able to revitalize its aging PAH franchise with a safer, more potent drug.
Shares in Actelion Ltd. rose 13 percent Monday on news that macitentan, its dual endothelin receptor antagonist (ERA), hit the primary endpoint in a pivotal Phase III trial in pulmonary arterial hypertension (PAH), raising the prospect that the company will be able to revitalize its aging PAH franchise with a safer, more potent drug.
Transgene SA hopes interim data from a Phase II trial of its therapeutic vaccine for treating hepatitis C virus (HCV) infection, TG4040, is sufficient to secure a deal for its further development.
Genzyme unveiled new disability data from the Care MS II Phase III head-to-head trial of its CD52-targeting antibody, Lemtrada (alemtuzumab), which confirmed its superiority over Rebif (interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (MS) who had relapsed on prior therapy.
Newly formed Galecto Biotech AB is taking a distinctive approach to inhibiting galectin-3, a newly emerging target in several disease areas, and to tackling idiopathic pulmonary fibrosis (IPF) as its lead indication.
Newly formed Galecto Biotech AB is taking a distinctive approach to inhibiting galectin-3, a newly emerging target in several disease areas, and to tackling idiopathic pulmonary fibrosis (IPF) as its lead indication.
In a second round of job cuts inside 12 months, Addex Therapeutics SA is seeking around 28 redundancies from its work force and is planning to intensify its use of outsourced R&D services.
Shares in TiGenix NV gained 5 percent Tuesday on news that Cx611, its adult stem cell therapy for rheumatoid arthritis (RA), hit a key safety milestone in a Phase IIa safety trial.
Hunter Immunology Ltd. gained a back door listing on the Australian Stock Exchange last week by completing its reverse takeover of publicly quoted probiotics firm Probiomics Ltd.
